Search results
Results From The WOW.Com Content Network
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
Six months ago Cassava Sciences (SAVA) had a problem. A citizen petition was logged with the FDA calling for a halt on the company's simufilam drug for the treatment of Alzheimer's Disease. The ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cassava Sciences wasn’t one of them. The 10 stocks that made ...
Early in October, I said that Cassava Sciences’ (NASDAQ:SAVA) big gains in late September had investors dreaming of a big payday for SAVA stock in 2022. Source: Pavel Kapysh / Shutterstock.com I ...
It’s been a miserable week for investors in clinical-stage biotechnology company Cassava Sciences (SAVA). The stock tumbled over 20% following a fireside chat, where CEO Remi Barbier outlined ...
If volatility is not your bag, then definitely stay away from Cassava Sciences (SAVA) stock. This biotech has been one of 2021’s most volatile, not to mention, controversial names. Ultimately ...
Since making some big moves last month Cassava Sciences (NASDAQ:SAVA) stock has largely traded sideways. Yet while SAVA stock has been acting less wild, don’t blame it on a lack of new developments.
Cassava Sciences (NASDAQ:SAVA) stock took off once again during September. Rumors about the Securities and Exchange Commission (or SEC) clearing its investigation of the scandal-tarnished biotech ...